Alliance A032201 STRIKE (High Risk Renal Cell Carcinoma) - Clinical Trial

If you choose to join this study, you will get a blood draw and have the study test run. Based on the results of the study test, you will then get a group assignment.

• Group A: You will be in this group if you have a "positive" first study test. People in this group will get a random assignment (by chance) to get either a single immunotherapy drug, called nivolumab, or a combination of two immunotherapy drugs, called nivolumab plus relatlimab. You will get the drug(s) through a vein in the arm once every 28 days. 28 days is called 1 cycle. You will receive up to 12 total cycles of immunotherapy treatment.
• Group B: You will be in this group if you have a "negative" first study test. People in this group will get a random assignment to get an immunotherapy drug called nivolumab or be on close monitoring without receiving initial immunotherapy. If you are assigned to receive immediate treatment with nivolumab, you will get this drug \through a vein in the arm once every 28 days. 28 days is called 1 cycle. You will receive up to 12 cycles. If you are assigned to close monitoring without immediate immunotherapy, you will be told if your Signatera test changes from negative to positive and then offered treatment with nivolumab at that time for up to 12 cycles if you have a later positive result.